Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%

Key Points

• Short interest in Entera Bio surged 286.7% to 1.15 million shares as of July 31, representing 2.6% of shares outstanding. Despite the increase, the stock’s days-to-cover ratio remained low at 0.2 days due to heavy average trading volume.
• Entera Bio shares opened at $2.80 after declining 6.7%, while the company reported a quarterly loss of $0.14 per share—worse than the $0.08-per-share consensus estimate.
• Analyst sentiment is mixed, with one Buy and one Sell rating producing a consensus “Hold” rating and a $9.00 price target. Institutional investors own 14.11% of the company.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,150,114 shares, an increase of 286.7% from the July 15th total of 297,452 shares. Based on an average daily trading volume, of 7,664,901 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.6% of the company's stock are short sold.

Entera Bio Trading Down 6.7%

Entera Bio stock opened at $2.80 on Thursday. The firm has a market capitalization of $138.01 million, a price-to-earnings ratio of -8.00 and a beta of 1.38. The firm has a 50 day simple moving average of $1.95 and a 200 day simple moving average of $1.52. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, equities research analysts forecast that Entera Bio will post -0.34 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ENTX. Superstring Capital Management LP purchased a new position in Entera Bio in the 4th quarter worth approximately $33,000. Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock valued at $77,000 after purchasing an additional 28,322 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after buying an additional 25,000 shares during the last quarter. Jane Street Group LLC increased its stake in Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock worth $144,000 after purchasing an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock valued at $210,000 after buying an additional 19,601 shares during the period. 14.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Entera Bio in a report on Friday, July 17th. HC Wainwright reissued a "buy" rating on shares of Entera Bio in a research report on Wednesday, June 24th. Finally, Wall Street Zen upgraded Entera Bio to a "sell" rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Entera Bio presently has an average rating of "Hold" and a consensus price target of $9.00.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source